Cardiovascular and Metabolic Disease Center
Mitochondrial Research Affinity Collaboration-Laboratories & Engineering

Home > 0

HerbalPharm Inc. Products Improve Stamina, Study Shows

  • 작성자한진
  • 작성일2006-12-30 16:09:48
  • 조회수1956
  • 첨부파일첨부파일
SEATTLE--(BUSINESS WIRE)--HerbalPharm, Inc. (Pink Sheets: HBPM - News), a Florida company ("HerbalPharm" or the "Company"), announced today that findings released from studies conducted at the Hong Kong University of Science and Technology (HKUST) on the Company's proprietary formula demonstrated that the key compound of the Company's products enables both long-term and balanced energy-level improvement by enhancing the functional capacities of the human body's vital organs. Additionally, it was determined that the key compound used in its products increases exercise endurance and performance through the strengthening of innate body conditions. ADVERTISEMENT Tests results demonstrated the additional positive effects of protecting muscles from exercise-induced damages by way of (i) enhancing the metabolism of liver glutathione and (ii) inducing the expression of heat shock proteins. Dr. Robert Ko, the Company's Co-founder and Head of Research commented, "These findings are significantly important to the legitimization of our products' efficacy. To my knowledge, no other product has shown the unique effects on anti-aging, muscle cell protection and stamina improvements." About the Company HerbalPharm, Inc. is a biotechnology company engaged in the research & development, marketing and sale of over-the-counter drugs, dietary supplements and functional beverages. The key compound used in the Company's products is based on the Company's patent pending proprietary formula of naturally occurring elements that is the result of over 15 years of research and development by one of its founding shareholders, the Hong Kong University of Science and Technology (HKUST). The compound has demonstrated, through scientific research, the ability to reverse mitochondrial decay due to aging. Mitochondrial decay is a current and popular theory as a leading cause of aging-related conditions. Scientific studies performed at HKUST have identified biochemical actions of HerbalPharm's key compound, demonstrating that it enhances the mitochondrial glutathione antioxidant status, a crucial factor in maintaining mitochondrial function and cell survival, and induces the expression of heat shock proteins, another group of important molecules for cell protection. Management's research indicates that these biochemical actions are advantageous, when compared to any other identified compounds, either synthetic or naturally occurring, in protecting important organs, including the heart, liver and brain. With its products, HerbalPharm aims to satisfy the needs of the "Baby Boomers," the heart-health and heart-disease markets and the segment of the population that is physically active. The Company has the ability to become a formidable player in the biotechnology industry. The Company has a capitalization of 28,469,298 shares of common stock issued and outstanding. Forward-Looking Statements This news release includes forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. While these statements are made to convey to the public the Company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the Company at this time, actual results may differ materially from those described. Additional factors that could materially affect these forward-looking statements and/or predictions include, among other things: (1) our ability to manage the HPW acquisition and the expansion of operations; (2) our ability to obtain contracts with suppliers of raw materials and distributors of our products; (3) the risks inherent in the mutual performance of such supplier and distributor contracts (including our production performance); (4) our ability to protect and defend our proprietary technology; (5) our ability to secure and retain management capable of managing growth; (6) our ability to raise necessary financing to execute the Company's business plans; and (7) the Company's ability to comply with all applicable federal, state and local government and international rules and regulations. Corporate Services by: EquityDigest.com
Total404 [ page1/27 ]
No. 제목 작성자 작성일 조회수
404 인제대, 과기정통부 ‘2023년도 기초연구실 지원사업’ 선정 2023.09.13 관리자 (web_admin) 2023.09.13 7
403 인제대 교수팀 '돌연사 주범 심부전 원인 규명' 2023.09.13 관리자 (web_admin) 2023.09.13 5
402 2022학년도 인제학술상 수상자 선정 결과 2023.01.05 관리자 2023.01.05 57
401 안전관리 우수연구실 인증 취득 2023.01.05 관리자 2023.01.05 40
400 한진교수 화의자의학상 수상 2023.01.05 관리자 2023.01.05 57
399 이온통로 학회 -Amy 포스터상 수상 2019.01.15 김형규 2019.01.15 2,587
398 센터 겸임교수 조성우 교수 - 한빛사 -JACC Vascular Imaging 2018.12.08 김형규 2018.12.08 2,791
397 2017 IMPACT Symposium 개최 첨부파일 2017.10.31 김보현 2017.10.31 2,588
396 경암바이오유스 2017 첨부파일 2017.08.11 김보현 2017.08.11 2,871
395 KORUS 2017 첨부파일 2017.06.21 김보현 2017.06.21 2,986
394 IMPACT 2016 심포지엄 개최 안내 첨부파일 2016.04.18 관리자 2016.04.18 4,000
393 IMPACT 2015 심포지엄 개최 안내 첨부파일 2015.04.20 서대윤 2015.04.20 2,869
392 2015 중점연구소 성과 전시회 첨부파일 2015.03.31 김형규 2015.03.31 2,462
391 Best Miso Award - 한진 2014.11.04 이정훈 2014.11.04 2,072
390 신진생리학자상 - 김형규 2014.10.29 이정훈 2014.10.29 1,816
처음이전1 2 3 4 5 6 7 8 9 10 다음 마지막